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ADHD: Overview and Heritability 	 Attention	deficit	hyperactivity	disorder	(ADHD)	is	a	mental	disorder	that	is	primarily	categorized	by	lack	of	sustained	attention,	impulsive	behavior,	and	hyperactivity	(Barkley,	1997).	These	symptoms	are	usually	first	presented	in	early	childhood	and	do	not	diminish	overtime,	but	rather	continue	into	adulthood	in	50-80%	of	cases.	Individuals	with	ADHD	are	often	at	risk	of	lower	achievement	in	school	due	to	their	short	attention	span	and	hyperactivity,	as	well	as	behavioral	and	social	problems	due	to	their	impulsive	tendencies	(Barkley,	1997).	When	ADHD	was	first	discovered	in	the	early	1900s,	its	symptoms	were	thought	to	be	a	result	of	lack	of	motivation	and	irregular	behavior	due	to	skewed	morality	(Still,	1902).	Over	a	decade	later	it	has	become	very	clear	that,	while	there	may	be	environmental	risks	associated	with	the	acquisition	of	ADHD,	the	disorder	can	be	mostly	explained	by	molecular	biology	and	genetics	(Faraone	et	al.,	2005).	To	confirm	the	heritability	of	ADHD,	many	case	studies	have	been	done	to	look	for	a	familial	linkage.		By	controlling	for	environmental	factors	such	as	family	make-up	and	socioeconomic	status,	it	has	been	shown	that	children	with	parents	who	have	ADHD	are	two	to	eight	times	more	likely	to	also	have	the	disorder,	simply	due	to	genetics	(Faraone	et	al.,	2005).		This	genetic	factor	was	further	confirmed	by	studying	twins	to	see	if	identical	twins,	who	share	identical	DNA,	are	more	likely	to	jointly	inherit	ADHD	than	fraternal	twins,	who	only	share	half	of	their	DNA.	By	comparing	the	heritability	among	20	studies	of	twins	in	the	United	States,	it	was	confirmed	that	the	average	heritability	of	ADHD	is	76%,	making	it	one	of	the	most	heritable	psychiatric	disorders	in	existence	(Coolidge	et	al.,	2000).		 While	ADHD	can	be	clearly	established	as	a	genetic	disorder,	the	exact	mechanistic	causes	have	not	been	confirmed,	though	a	multitude	of	studies	have	been	and	are	being	
done	to	identify	specific	genes	and	their	effects	on	the	development	of	the	disorder.	Biologically	relevant	genes,	those	whose	physiological	roles	would	theoretically	influence	ADHD	development,	have	been	studied	in	affected	patients	and	control	subjects.	Allele	frequencies	are	used	to	determine	alleles	that	are	more	commonly	present	in	ADHD	patients,	indicating	a	possible	genetic	risk	for	the	disorder	(Barkley,	1997).	Also,	mutations	in	relevant	genes	that	are	present	in	ADHD	patients	can	be	a	likely	cause	of	the	disorder	if	subjects	with	the	wild-type	gene	are	mostly	unaffected.	Genes	involved	in	neurotransmitter	pathways,	such	as	dopamine	and	serotonin	systems,	have	been	heavily	studied	and	are	the	current	strongest	candidates	for	a	molecular	basis	for	ADHD.		 This	review	will	discuss	polymorphisms	in	genes	that	are	involved	in	different	neurological	systems	associated	with	ADHD.	The	most	established	and	first-studied	system	is	the	dopaminergic	system,	which	is	responsible	for	the	mobilization	and	re-uptake	of	dopamine,	a	neurotransmitter	that	contributes	to	the	brain’s	reward	system	(Thapar	et	al.,	2005).	The	next	system,	the	serotoninergic	system,	is	mechanistically	similar	to	its	dopaminergic	counterpart,	but	involves	the	neurotransmitter	serotonin,	which	contributes	to	aggression	and	impulse	control	(Virkkunen	et	al..	1995).	Finally,	the	noradrenergic	system	will	be	discussed,	due	to	its	role	in	norepinephrine	release,	which	is	associated	with	cognitive	and	nervous	system	functions	(Arnsten	et	al.,	1996).		
Polymorphisms	in	Dopaminergic	Genes		 The	dopaminergic	neurotransmitter	system	has	been	the	most	extensively	studied	in	relation	to	ADHD,	due	to	neurological	and	pharmacological	evidence	confirming	its	involvement	in	the	disorder	(Thapar	et	al.,	2005).	This	involvement	is	most	clearly	seen	in	the	high	response	rate	of	ADHD	to	stimulant	medications	that	increase	the	availability	of	
dopamine,	such	as	methylphenidate,	which	inhibits	the	dopamine	transporter	DAT1	(Cortese	and	Castellanos,	2012).	DAT1,	encoded	by	the	gene	SLC6A3,	is	involved	in	reuptake	of	dopamine	from	the	synaptic	cleft,	diminishing	its	effects	in	the	brain	by	reducing	its	availability	to	bind	and	activate	receptors	(Šerý	et	al.,	2015).	Because	of	the	success	of	dopamine-enhancing	drugs	in	relieving	symptoms	of	ADHD,	it	is	reasonable	to	believe	that	the	dopaminergic	system	has	a	critical	role	in	the	disease	mechanism	and	mutations	in	genes	encoding	for	proteins	in	this	system	may	cause	ADHD.			 The	first	candidate	gene	studied	in	the	dopaminergic	system	was	DAT1.	Some	patients	with	ADHD	have	a	high	risk	of	a	10-repeat	allele	in	the	SLC6A3	gene,	causing	excess	copies	of	the	DAT1	protein	(Heinz	et	al.,	2000).	Extra	copies	of	a	dopamine	re-uptake	protein	would	theoretically	cause	a	lack	of	dopamine	availability	in	an	individual,	contributing	to	an	ADHD	phenotype	via	decreased	dopaminergic	functions.	However,	the	finding	of	altered	DAT1	levels	in	diseased	patients	has	not	been	consistently	reproduced,	so	it	is	difficult	to	confirm	that	this	is	a	true	genetic	cause	of	ADHD.	In	a	study	by	Swanson	et	al.	(2000),	the	high-risk	DAT1	allele	actually	occurred	more	often	in	control	subjects	than	in	ADHD	patients.	This	may	have	been	due	to	a	small	sample	size	producing	skewed	results,	but	it	is	still	important	to	explore	other	dopaminergic	genes	in	order	to	establish	a	relation	between	the	neurotransmitter	system	and	ADHD.		 Another	gene	that	has	been	extensively	studied	in	relation	to	ADHD	is	the	dopamine	D4	receptor	gene	(DRD4).	When	activated	by	dopamine,	this	receptor	is	involved	in	attention,	motivation,	and	reward	mechanisms	(Robbins	and	Everitt,	1996).	An	allele	for	DRD4	containing	seven	repeats	in	the	third	exon	has	been	associated	with	ADHD	as	well	as	externalized	aggressive	behavior	in	children	(Bakermans-Kranenburg	et	al.,	2008).	This	is	
because	the	7-repeat	allele	has	a	decreased	affinity	for	dopamine,	due	to	a	mutation	in	the	DRD4	protein	that	results	in	a	conformational	change	in	a	cytoplasmic	loop	of	the	receptor	(Tovo-Rodrigues	et	al.,	2013).	While	the	exact	mechanism	for	neuro-functional	problems	in	ADHD	patients	with	mutated	DRD4	is	not	completely	understood,	it	is	possible	that	the	protein	is	important	in	motivational	processes	in	the	brain,	due	to	its	prevalence	in	the	prefrontal	cortex	(Primus	et	al.,	1997).	A	study	by	Shaw	et	al.	(2007)	showed	that	the	7-repeat	allele	for	DRD4	is	associated	with	decreased	cortical	thickness	in	the	frontal	lobe	of	the	brain,	which	may	be	a	cause	of	the	neurological	symptoms	of	ADHD.	This	hypothesis	correlates	with	the	“motivational	pathway”	that	ADHD	symptoms	can	take,	which	occurs	when	the	reward	mechanisms	of	the	brain	(located	in	the	frontal	cortex)	are	not	functional,	resulting	in	behavior	problems,	impulsiveness,	and	difficulty	engaging	in	tasks	(Toplak	et	al.,	2005).	
Polymorphisms	in	Serotoninergic	Genes		 While	the	dopaminergic	neurotransmitter	system	clearly	contains	susceptible	genes	for	ADHD	development,	studies	have	shown	that	serotonin	neurotransmission	also	has	an	important	role	in	the	genetics	of	this	disorder.	Lack	of	serotonin	impacts	many	mental	processes	such	as	anxiety	and	depression	and	has	been	associated	with	lack	of	impulse	control	(Virkkunen	et	al..	1995).	Serotonin	levels	are	typically	low	in	blood	platelets	of	ADHD	patients	and	their	cerebrospinal	fluid	contains	higher	levels	of	5-hydroxyindoleacetic	acid,	a	metabolite	of	serotonin	synthesis	(Ribasé	et	al.,	2009).	Also,	mice	models	for	ADHD	have	shown	decreased	hyperactivity	when	given	serotonin	agonists	and	serotonin	reuptake	inhibitors,	which	both	increase	the	amount	of	serotonin	or	serotonin-like	molecules	in	the	body	(Gainetdinov	et	al.,	1999).		
	 There	are	fourteen	receptors	involved	in	serotonin	recognition	with	serotonin	receptor	1B	(5-HT1B	)	present	in	most	mammals,	including	humans	(Bouwknecht	et	al.,	2001).	In	humans,	polymorphisms	of	this	receptor	are	associated	with	antisocial	behavior	and	addiction	(Lappalainen	et	al.,	1998).	In	addition,	mice	lacking	5-HT1B	receptors,	accomplished	via	gene	knockout,	were	more	hyperactive	and	aggressive	than	wild	mice	that	had	normal	levels	of	the	serotonin	receptor	(Bouwknecht	et	al.,	2001).	This	association	was	further	confirmed	in	humans	by	examining	polymorphisms	in	the	HTR1B	gene,	which	encodes	for	the	5-HT1B	receptor	(Smoller	et	al.,	2006).	The	G861C	variant	of	the	gene	and	a	polymorphism	in	the	3’	UTR	of	HTR1B	(A1180G)	are	associated	with	ADHD,	possibly	due	to	a	mutated	receptor	in	the	G861	variant	and	decreased	mRNA	stability	via	poly-A	tail	damage	in	the	A1180G	variant	(Smoller	et	al.,	2006).		The	serotonin	receptor	2A	gene	(5HT2A)	may	also	be	involved	in	ADHD,	with	a	SNP	in	exon	three	of	the	gene	leading	to	combined	ADHD	subtypes	in	a	study	of	451	adult	and	children	patients	(Ribasé	S	et	al.,	2009).	Notably,	the	receptor	encoded	by	5HT2A	is	also	utilized	in	dopamine	neurotransmission	by	inhibiting	dopamine	release,	a	known	cause	of	hyperactivity	(O’Neill	et	al.,	1999).	This	shows	that	the	serotonergic	system	make	contribute	to	ADHD	through	its	involvement	in	the	dopaminergic	system,	rather	than	the	two	pathways	acting	independently.	This	interaction	was	tested	in	DAT	knockout	mice,	which	were	lacking	a	dopamine	receptor.	Exogenous	5HT2A	receptor	agonists	were	added	to	the	mice	and	they	showed	reduced	signs	of	hyperactivity,	indicating	that	inhibition	of	the	serotoninergic	receptor	led	to	increased	dopamine	availability,	even	when	dopamine	receptors	were	lacking	(Gainetdinov	et	al.,	1999).	Further	studies	are	required	to	confirm	mechanisms	that	may	cause	ADHD	based	on	interactions	between	dopamine	and	serotonin	
pathways,	but	it	is	clear	that	some	type	of	connection	exists	between	the	relatedness	of	these	pathways	and	hyperactivity.		
Polymorphisms	in	Adrenergic	Genes		 The	noradrenergic	system	is	responsible	for	mobilizing	the	neurotransmitter/hormone	norepinephrine	in	response	to	stress,	enhancing	focus	and	stimulating	the	nervous	system	of	an	individual	to	increase	alertness	(Arnsten	and	Li,	2005).	In	the	absence	of	stress,	norepinephrine	in	the	prefrontal	cortex	of	the	brain	serves	to	enhance	cognitive	function	by	activating	adrenergic	receptors	that	are	associated	with	noradrenergic	terminals	(Arnsten	et	al.,	1996).	Norepinephrine	receptors	and	transporters	have	been	extensively	studied	in	relation	to	ADHD	and	polymorphisms	in	genes	encoding	for	these	receptors	may	make	individuals	more	susceptible	to	the	disorder.			 The	alpha-2A	adrenergic	receptor	(ADRA2A)	has	been	examined	in	case	studies	of	ADHD	patients	and	a	SNP	at	nucleotide	1291	in	the	gene	(C	to	G)	has	been	associated	with	ADHD	symptoms	in	patients	with	Tourette’s	syndrome	(Comings	et	al.,	2003).	Similarly,	a	family-based	study	in	ADHD	patients	showed	a	significant	correlation	between	the	ADRA2A	allele	with	guanine	at	position	1291	and	lack	of	sustained	attention	(Roman	et	al.,	2003).	However,	a	similar	association	between	a	polymorphism	in	the	alpha-2C	adrenergic	receptor	(ADRA2C)	and	ADHD	was	not	significant	after	statistical	analysis,	a	finding	that	has	been	replicated	in	family	studies	(Barr	et	al.,	2001).	Because	of	the	lack	of	solid	evidence	to	suggest	that	mutations	in	adrenergic	receptors	cause	ADHD-risk,	it	is	important	to	study	other	aspects	of	the	noradrenergic	system.			 The	norepinephrine	transporter,	encoded	by	the	SLC6A2	gene,	has	also	been	analyzed	in	ADHD	patients,	mainly	due	its	pharmacological	significance.		Drugs	that	block	
this	transporter	are	highly	effective	in	the	treatment	of	behavioral	ADHD	symptoms	such	as	hyperactivity	and	lack	of	sustained	attention	(Biederman	and	Spencer,	2000).	In	the	Comings	et	al.	(2003)	study	of	patients	with	Tourette’s	syndrome,	there	was	an	association	between	a	polymorphism	in	SLC6A2	and	ADHD	symptoms.	However,	in	a	study	examining	122	families	with	genetic	ADHD,	there	was	no	evidence	to	suggest	that	polymorphisms	in	SLC6A2	were	disease-causing	(Barr	et	al.,	2002).			 While	polymorphisms	in	noradrenergic	system	genes	have	not	been	conclusively	linked	to	ADHD,	there	is	clearly	some	type	of	connection	between	this	neurotransmitter	system	and	disordered	phenotypes.	This	may	be	a	result	of	the	interconnected	effects	of	the	norepinephrine	and	dopamine	pathways.	For	example,	norepinephrine	acts	as	a	dopamine	agonist	on	the	dopamine	D4	receptor	(Lanau	et	al.,	2002).	This	could	explain	the	reason	why	inhibiting	the	norepinephrine	transporter	is	effective	in	treating	ADHD,	even	though	there	is	no	clear	evidence	that	norepinephrine	receptors	are	involved	in	the	disorder.	The	increased	availability	of	norepinephrine	as	a	result	of	blocking	re-uptake	transporters	may	allow	the	molecule	to	bind	and	activate	DRD4,	rather	than	just	ADRA2A,	relieving	ADHD	symptoms	by	activating	the	dopaminergic	system.	More	research	is	needed	to	confirm	this	hypothesis	or	any	clear	involvement	of	the	noradrenergic	system	in	ADHD.		
Conclusion:	Neurotransmitter	involvement	in	ADHD		 Attention	deficit	hyperactivity	disorder	is	a	neurological	disorder	with	many	possible	causes,	including	mutations	in	genes	that	are	involved	in	neurotransmitter	pathways.	The	dopaminergic	system,	responsible	for	utilizing	dopamine,	is	essential	in	reward-motivated	behavior.	Lack	of	this	molecule	potentially	causes	impulsive	behavior	and	difficulty	focusing	on	tasks,	two	symptoms	of	ADHD.	Polymorphisms	in	dopamine	
receptor	and	transporter	genes	have	been	studied,	with	DAT1	and	DRD4	showing	the	highest	likelihood	of	being	linked	to	ADHD.	The	serotoninergic	system	mobilizes	serotonin,	which	aids	in	impulse	control	and	keeps	anxiety	at	bay.	Without	adequate	levels	of	this	neurotransmitter,	ADHD-associated	hyperactivity	can	occur	in	an	individual.	Polymorphisms	in	the	serotonin	receptors	5-HT1B	and	5HT2A	have	been	shown	to	be	associated	with	ADHD.	Finally,	the	noradrenergic	system	is	responsible	for	the	release	of	norepinephrine,	a	hormone	that	can	act	as	a	neurotransmitter	in	the	brain	to	aid	in	cognitive	function	and	focus.	While	no	clear	evidence	has	been	found	to	establish	this	system’s	involvement	in	ADHD,	the	norepinephrine	receptor	ADRA2A	and	transporter	SLC6A2	have	been	shown	in	some	cases	to	be	mutated	in	ADHD	patients.	A	more	likely	explanation	of	this	system’s	involvement	in	the	disorder	is	through	its	relationship	to	the	dopaminergic	system,	which	has	already	been	established	as	a	factor	in	ADHD.		
Future	Directions:	Novel	Gene	Studies	and	ADHD	Treatments		 Future	candidate	gene	studies	are	needed	to	provide	statistically	significant	results	that	detect	a	true	association	between	neurotransmitter	system	genes	and	ADHD.	Increasing	the	sample	size	of	case	and	family	studies,	as	well	as	exploring	novel	genes	that	may	be	more	directly	related	to	the	disorder	phenotype,	may	provide	more	cohesive	results.		Genome-wide	association	studies	(GWAS)	between	ADHD	and	another	neurological	disorder	that	shares	similar	phenotypes	could	be	done	to	discover	novel	genes	that	are	involved	in	ADHD,	which	could	possibly	have	significant	risk-causing	alleles.	A	very	recent	GWAS	between	ADHD	and	obsessive	compulsive	disorder	(OCD),	which	shares	similar	pathology	to	ADHD,	showed	limited	genetic	overlap,	indicating	that	this	method	needs	to	be	used	more	and	be	deemed	successful	to	reliably	find	novel	genes	that	are	
involved	in	ADHD	(Ritter	et	al.,	2017).	In	addition,	when	studying	a	candidate	gene,	multiple	polymorphisms	should	be	examined	rather	than	only	one	or	a	few	specific	mutations.	While	one	or	two	conserved	mutations	may	be	highly	present	in	a	population	of	interest,	this	does	not	mean	that	they	are	necessarily	most	likely	to	cause	ADHD.	Finally,	although	correlations	between	genetic	mutations	and	ADHD	symptoms	have	been	discovered,	precise	mechanisms	for	these	associations	need	further	research.	Studying	gene-to-gene	as	well	as	gene-to-environment	interactions	could	provide	more	detailed	explanations	of	why	polymorphisms	in	certain	genes	lead	to	ADHD	phenotypes.		Establishing	genes	that	are	involved	in	ADHD	would	provide	knowledge	that	has	clinical	significance,	allowing	pharmacologists	to	know	precisely	what	proteins	to	target	with	drugs	and	even	what	genes	to	target	with	gene	therapy.	This	could	reduce	the	use	of	stimulant	drugs	to	treat	ADHD,	such	as	the	popular	amphetamine	Adderall,	which	have	potentially	dangerous	cardiac	side	effects	due	to	their	role	in	increasing	heart	rate	and	blood	pressure	(Sinha	et	al.,	2016).	Designing	drugs	that	inhibit	or	activate	specific	proteins	that	are	encoded	by	genes	known	to	be	involved	in	ADHD	would	result	in	more	specific	treatment	plans	and	less	adverse	drug	effects,	potentially	improving	the	quality	of	life	of	ADHD	patients.			 	
	Figure	1.	Mutations	in	the	DNA	sequence	of	the	HTR1B	gene	results	in	either	mutant	
5-HT1B	protein	or	unstable	mRNA	transcript,	both	of	which	may	cause	ADHD.	Left:	The	HTR1B	gene	codes	for	wild	type	5-HT1B	serotonin	transporter	protein	(PDB	ID:	4IAR)	when	there	are	no	mutations	in	the	DNA.	Middle:	When	HTR1B	carries	the	G861C	mutation,	the	resulting	5-HT1B	protein	is	mutated,	leading	to	ADHD	symptoms.	Right:	When	HTR1B	has	the	A1180G	mutation,	the	5-HT1B	protein	is	not	made	due	to	degradation	of	unstable	mRNA,	also	leading	to	ADHD	symptoms.	Crystal	structure	of	5-HT1B	obtained	from	Wang	et	al.	(2013).	 	
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